MILFORD, Mass., SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced that it has entered into a definitive agreement to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries. Under the terms of the agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share, representing a 25% premium to the 30-day volume-weighted average stock price. The agreement was unanimously approved by SeraCare’s Board of Directors.

Greg Gould, Interim President and Chief Executive Officer and Chief Financial Officer commented, “SeraCare’s commitment to providing vital products and services of the highest quality has driven our growth and diversification across a blue chip life sciences customer base. Linden is a natural strategic fit for SeraCare with a proven record of operating successful companies in the healthcare and life sciences sectors. Linden’s acquisition of SeraCare recognizes our accomplishments and translates them into significant value for our shareholders.”

“SeraCare’s product offerings, services and strong customer base provide an attractive foundation on which to compete and grow in the global high-growth markets of human diagnostics and therapeutics research and development,” said Fran Lunger, a Linden Operating Partner and former CEO of Millipore Corporation.

A special meeting of SeraCare’s shareholders will be held after the preparation and filing of a proxy statement with the Securities and Exchange Commission and subsequent mailing to shareholders. If the merger is approved by shareholders, the transaction is expected to close in the second quarter of calendar year 2012. The transaction is subject to various closing conditions, including the receipt of regulatory approvals, but is not subject to a financing condition. Upon completion of the acquisition, SeraCare will become a private company, wholly owned by an affiliate of Linden.

Lazard is acting as exclusive financial advisor to SeraCare and has provided a fairness opinion to the SeraCare Board of Directors. Foley Hoag LLP is serving as SeraCare’s outside counsel. William Blair & Company, L.L.C. is acting as Linden’s financial advisor, and Kirkland & Ellis LLP is serving as legal counsel to Linden.

About Linden Capital Partners:

Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s investment strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden has advised SeraCare that it currently manages $575 million in capital. For additional information, please visit www.lindenllc.com.

About SeraCare Life Sciences, Inc.:

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare’s quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry. For additional information, please visit www.seracare.com.